|Bid||50.50 x 1400|
|Ask||52.30 x 800|
|Day's Range||51.25 - 52.22|
|52 Week Range||44.76 - 54.26|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||9.01|
|Forward Dividend & Yield||1.93 (3.70%)|
|Ex-Dividend Date||May 03, 2021|
|1y Target Est||N/A|
Dr. Manish Garg, Emergency Medicine Physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sanofi SA's (NASDAQ: SNY) avalglucosidase alfa for Pompe disease. The positive opinion is based on Phase 3 COMET study data, which showed avalglucosidase alfa improved respiratory function and movement endurance measures. Avalglucosidase alfa is a long-term enzyme replacement therapy designed to target the mannose-6-phosphate (M6P) receptor, the underlying disease mechan
Dr. Gustavo Ferrer, President of Aventura Pulmonary Institute, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.